Q2 EPS Forecast for Enlivex Therapeutics Lifted by Analyst

Enlivex Therapeutics Ltd. (NASDAQ:ENLV) – Analysts at HC Wainwright boosted their Q2 2026 EPS estimates for shares of Enlivex Therapeutics in a research note issued on Wednesday, July 1st. HC Wainwright analyst R. Selvaraju now expects that the company will post earnings per share of ($0.30) for the quarter, up from their previous estimate of ($0.30). HC Wainwright has a “Buy” rating and a $300.00 price objective on the stock. The consensus estimate for Enlivex Therapeutics’ current full-year earnings is ($1.19) per share. HC Wainwright also issued estimates for Enlivex Therapeutics’ Q3 2026 earnings at ($0.30) EPS, Q4 2026 earnings at ($0.30) EPS, FY2026 earnings at ($1.19) EPS, Q1 2027 earnings at ($0.30) EPS, Q2 2027 earnings at ($0.30) EPS, Q3 2027 earnings at ($0.30) EPS, Q4 2027 earnings at ($0.30) EPS and FY2027 earnings at ($1.34) EPS.

A number of other analysts have also recently commented on the stock. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Enlivex Therapeutics in a research report on Friday, June 26th. Wall Street Zen raised Enlivex Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, April 25th. One equities research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $247.50.

Enlivex Therapeutics Stock Performance

NASDAQ:ENLV opened at $6.86 on Monday. Enlivex Therapeutics has a 52 week low of $6.42 and a 52 week high of $31.50. The firm’s fifty day moving average is $10.15 and its 200-day moving average is $13.19. The firm has a market cap of $115.52 million, a P/E ratio of -0.83 and a beta of 1.52.

Institutional Trading of Enlivex Therapeutics

Large investors have recently made changes to their positions in the company. Renaissance Technologies LLC grew its stake in Enlivex Therapeutics by 99.4% in the fourth quarter. Renaissance Technologies LLC now owns 313,628 shares of the company’s stock valued at $221,000 after acquiring an additional 156,336 shares during the period. HRT Financial LP raised its position in shares of Enlivex Therapeutics by 719.4% during the fourth quarter. HRT Financial LP now owns 153,990 shares of the company’s stock worth $108,000 after purchasing an additional 135,198 shares during the period. Jane Street Group LLC raised its position in shares of Enlivex Therapeutics by 527.4% during the first quarter. Jane Street Group LLC now owns 80,759 shares of the company’s stock worth $78,000 after purchasing an additional 67,886 shares during the period. Invesco Ltd. bought a new position in shares of Enlivex Therapeutics in the 4th quarter worth $43,000. Finally, Susquehanna International Group LLP bought a new position in shares of Enlivex Therapeutics in the 3rd quarter worth $57,000. 1.02% of the stock is currently owned by institutional investors and hedge funds.

Key Stories Impacting Enlivex Therapeutics

Here are the key news stories impacting Enlivex Therapeutics this week:

• Positive Sentiment: HC Wainwright maintained a Buy rating and a $300 price target, signaling continued long-term optimism about Enlivex Therapeutics. Enlivex Therapeutics Stock Quote
• Neutral Sentiment: The analyst made small upward tweaks to several quarterly and annual EPS forecasts for 2026-2027, but the company is still expected to post losses throughout the period. Enlivex Therapeutics Stock Quote
• Negative Sentiment: Despite the bullish rating, the repeated EPS estimates remain negative, which may be weighing on investor confidence and contributing to the stock’s decline. Enlivex Therapeutics Trading Down 8.8% – Time to Sell?

Enlivex Therapeutics Company Profile

Enlivex Therapeutics is a clinical-stage biopharmaceutical company headquartered in Ness Ziona, Israel, that focuses on developing innovative immunotherapies for life-threatening inflammatory conditions. Founded in 2015, the company trades on the NASDAQ under the symbol ENLV and leverages a proprietary cell-based platform to restore immune balance in critical care settings.

The company’s lead product candidate, Allocetra, comprises reprogrammed apoptotic cell therapy designed to recalibrate the innate immune system.